EU/3/12/1061

About

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2016 on request of the sponsor.

On 8 November 2012, orphan designation (EU/3/12/1061) was granted by the European Commission to MedImmune Ltd, United Kingdom, for tralokinumab for the treatment of idiopathic pulmonary fibrosis.

Key facts

Active substance
Tralokinumab
Disease / condition
Treatment of idiopathic pulmonary fibrosis
Date of first decision
08/11/2012
Outcome
Withdrawn
EU designation number
EU/3/12/1061

Review of designation

Please note that this product was withdrawn from the Community Register of designated orphan medicinal products in August 2016 on request of the sponsor.

Sponsor's contact details

MedImmune Ltd
Milstein Building
Granta Park
Great Abington
Cambridgeshire
CB21 6GH
United Kingdom
Tel. +44 (0)1223 471 471
Fax +44 (0)1223 471 472
E-mail: tommasinii@medimmune.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating